Curis Regains Nasdaq Compliance, Remains Under Monitoring Period

Curis ( (CRIS) ) has provided an announcement.

On February 3, 2026, Curis, Inc. announced that it had received written notice from Nasdaq that the company had regained compliance with Nasdaq Listing Rule 5550(b)(2), restoring full compliance with the conditions previously set by a Nasdaq Hearings Panel. As a result, Curis remains listed on Nasdaq but will be subject to a one-year discretionary panel monitoring period, during which any new listing-rule deficiency could lead directly to a delisting determination, limiting Curis’s ability to obtain additional cure periods and raising the stakes for maintaining compliance for shareholders and other stakeholders.

The most recent analyst rating on (CRIS) stock is a Hold with a $0.89 price target. To see the full list of analyst forecasts on Curis stock, see the CRIS Stock Forecast page.

Spark’s Take on CRIS Stock

According to Spark, TipRanks’ AI Analyst, CRIS is a Neutral.

The score is held down primarily by weak financial durability (negative equity, higher debt, and continued cash burn) and bearish technicals (below key moving averages with negative MACD). Offsetting factors include constructive clinical/program updates and financing actions that may extend runway, but execution and funding/dilution risks remain central.

To see Spark’s full report on CRIS stock, click here.

More about Curis

Curis, Inc. is a biotechnology company whose shares are listed on the Nasdaq Stock Market. As a Nasdaq-listed issuer, Curis is subject to Nasdaq’s continued listing standards, including minimum market value and other financial and governance requirements that affect its access to public equity markets and visibility with investors.

Average Trading Volume: 485,744

Technical Sentiment Signal: Sell

Current Market Cap: $13.32M

See more insights into CRIS stock on TipRanks’ Stock Analysis page.